Xyzagen, Inc. Highlights Breakthrough Kv7 Channel Opener Chemistry at AES 2024
Pittsboro, NC – December 15, 2024
Xyzagen, Inc., a leading pharmacokinetics consultancy and boutique CRO, presented research on its novel Kv7 channel opener compounds at the American Epilepsy Society (AES) Annual Meeting, held December 6–10, 2024, in Los Angeles, CA
The research, titled “New Kv7 Channel Opener Chemistry for the Treatment of Seizures,” showcased promising pharmacological properties of the new chemistry, designed to treat disorders associated with neuronal hyperexcitability, including epilepsy. The findings demonstrated potentially significant advancements over existing clinical development therapies, positioning these compounds as strong candidates for clinical development.
Key Presentation Insights
“The AES Annual Meeting provided an invaluable opportunity to share our novel Kv7 chemistry with the epilepsy research community,”
said Chris Crean, Founder and CEO of Xyzagen. “These compounds represent a step forward in addressing the unmet medical needs of patients with epilepsy and other neurological disorders and provide another potential treatment within the expanding clinical Kv7 therapeutic space.”
Presentation Summary
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late-stage clinical noncompartmental PK, PopPK, and Quantitative Medicine.
Our knowledge in pharmacology/pharmacogenomics and in vitro/in vivo pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. We’re a boutique organization which allows for small clients and CROs to work directly with experts.
